2.07

1.90% -0.04

After Hours: 2.07

Can-Fite Biopharma Ltd ADR (CANF)

Overview News Price History Discussions Forecast Stock Split

Can-Fite Biopharma Ltd ADR stock is currently priced at $2.07, with a 24-hour trading volume of 15,768. It has seen a -1.90% decreased in the last 24 hours and a -11.91% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $2.18 pivot point. If it approaches the $2.04 support level, significant changes may occur.

Previous Close:

$2.11

Open:

$2.15

24h Volume:

15,768

Market Cap:

$10.33M

Revenue:

$743.00K

Net Income/Loss:

$-7.63M

P/E Ratio:

-0.88

EPS:

-2.3523

Net Cash Flow:

1W Performance:

+0.00%

1M Performance:

-11.91%

6M Performance:

-3.72%

1Y Performance:

-1.90%

1D Range:

$2.07

$2.15

52W Range:

$1.81

$3.33

Can-Fite Biopharma Ltd ADR Stock (CANF) Company Profile

Name

Can-Fite Biopharma Ltd ADR

Sector

Healthcare (1216)

Industry

Biotechnology (698)

Phone

972 3 924 1114

Address

10 Bareket Street, Kiryat Matalon PO Box 7537, Petah-Tikva

Employee

Twitter

@CanFitePharma

Next Earnings Date

2024-05-30

Latest SEC Filings

CANF's Discussions on Twitter

Can-Fite Biopharma Ltd ADR Stock (CANF) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-11-17	Initiated	Maxim Group	Buy
Oct-19-16	Resumed	ROTH Capital	Buy
Aug-29-16	Resumed	Rodman & Renshaw	Buy
Nov-30-15	Reiterated	H.C. Wainwright	Buy
Mar-31-15	Reiterated	H.C. Wainwright	Buy
Mar-30-15	Downgrade	ROTH Capital	Buy → Neutral
Dec-29-14	Reiterated	ROTH Capital	Buy
Nov-18-14	Initiated	H.C. Wainwright	Buy

View All

Can-Fite Biopharma Ltd ADR Stock (CANF) Latest News

Can-Fite (CANF) Up on Liver Cancer Study Update of Namodenoson

Zacks Investment Research

Can-Fite Announces Exercise of Warrants for Approximately $3.0 Million in Gross Proceeds

GlobeNewswire Inc.

3 Top Penny Stocks To Watch Before Next Week

PennyStocks

Can-Fite Biopharma Ltd ADR Stock (CANF) Financials Data

Can-Fite Biopharma Ltd ADR (CANF) Revenue 2024

CANF reported a revenue (TTM) of $743.00 thousand for the quarter ending December 31, 2023, a -8.27% decline year-over-year.

Can-Fite Biopharma Ltd ADR (CANF) Net Income 2024

CANF net income (TTM) was -$7.63 million for the quarter ending December 31, 2023, a +24.96% increase year-over-year.

Can-Fite Biopharma Ltd ADR (CANF) Earnings per Share 2024

CANF earnings per share (TTM) was -$3.00 for the quarter ending December 31, 2023, a 0.00% decline year-over-year.

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and liver diseases, as well as sexual dysfunction. The company's lead drug candidate is CF101 (Piclidenoson), which is in Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis. It also develops CF102 (Namodenoson) that is in Phase II clinical trials for the treatment of liver cancer and non-alcoholic fatty liver diseases, as well as for hepatocellular carcinoma and hepatitis C virus diseases; and CF602, which is in pre-clinical trial for the treatment of sexual dysfunction. Can-Fite BioPharma Ltd. was founded in 1994 and is headquartered in Petah-Tikva, Israel.